chemotherapy – UF Innovate

UF Biostatistician at the Forefront of Groundbreaking Childhood Leukemia Drug Trial

sooyoungryu — Tue, 18 Feb 2025 00:00:00 +0000

A clinical trial co-designed by UF researcher found that adding blinatumomab to chemotherapy significantly reduced relapse risk in children with acute lymphoblastic leukemia, marking a major breakthrough in treatment.

Adding one drug to a chemotherapy regimen for children with acute lymphoblastic lymphoma decreased risk of relapse by about two-thirds, according to a study designed in part by John Kairalla, Ph.D., the senior statistician on the clinical trial and research associate professor and associate program director of the Children’s Oncology Group Statistics and Data Center in the College of Public Health and Health Professions’ Department of Biostatistics.

Research Snapshot: Researchers Identify Genes That Predict Pediatric AML Outcomes

sooyoungryu — Wed, 15 Jan 2025 00:00:00 +0000

UF Health researchers have used a promising approach by integrating CRISPR-cas9-based drug screening with patients’ clinical outcome to identify genes and pathways that predict how patients will respond to the standard firstline chemotherapy treatment regimen used to treat patients with acute myeloid leukemia, or AML.

Led by Jatinder Lamba, Ph.D., co-leader of the UF Health Cancer Center’s Cancer Targeting and Therapeutics research program, the team identified genes that were associated with resistance or sensitivity to chemotherapy and linked these with patients’ treatment outcomes. The findings, published recently in the American Society of Hematology’s journal Blood Advances, could help develop new treatments to overcome resistance to chemotherapy.

Learn more about technologies discovered by Jatinder Lamba.

Targeting Protein Restores Aging Blood Cells, UF Researchers Find

sooyoungryu — Fri, 10 Jan 2025 00:00:00 +0000

As humans age, we develop chronic inflammation in our blood and tissues that gradually decreases the function of blood stem cells in our bone marrow. These defects harm blood cell production and the immune system, often leading to a slew of complications and weakening responses to chemotherapy.

UF Health Cancer Center researchers have discovered a way to prevent this inflammation, called “inflammaging,” by systemically targeting a protein. The findings in mice, published Jan. 3 in Science Immunology, could pave the way for therapies aimed at preserving an aging blood system, with implications for cancer treatments and aging-related diseases, including anemias, infections, and blood cancers.